$AKTX connected with @citybiznews to discuss the science and strategy behind PH1 and how Akari is building a smarter, more precise approach to cancer treatment. Read the full Q&A here:.🔗 . #AntibodyDrugConjugates #ADC #Oncology

$AKTX will be featured at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, August 19 at 2:00 PM ET. Join CEO Abizer Gaslightwala as he dives into our PH1 Spliceosome Modulating Payload & its potential to transform cancer therapy.

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. .$AKTX #AntibodyDrugConjugates #ADC #Oncology

Stay updated with Akari Therapeutics—subscribe to our email alerts and get the newest insights and company news sent directly to you. Sign up here: .$AKTX #AntibodyDrugConjugates #ADC #Oncology

Our CEO, Abizer Gaslightwala, shared his personal mission to transform cancer care in the Virtual Investor Summer Spotlight On Demand Conference. Catch up here: .$AKTX #AntibodyDrugConjugates #ADC #Oncology.

#DidYouSee: Abizer Gaslightwala, President and CEO, participated in a #VirtualInvestor #WhatThisMeans segment to discuss our novel spliceosome modulator payload, and its potential to disrupt key cancer-driving mechanisms. Catch up here: .$AKTX.

Akari Therapeutics Releases Virtual Investor “What This Means” Segment . .$AKTX #AntibodyDrugConjugates #ADC #Oncology

As we advance our PH1 payload for new ADCs, we are building our pipeline of additional ADC's beyond our lead candidate, a Trop2/PH1 ADC. Learn more here: .$AKTX #AntibodyDrugConjugates #ADC #Oncology

Current therapies often fall short due to limited efficacy, leaving critical unmet needs in Oncology. Our novel payload integrates immuno-oncology mechanisms into ADC technology to deliver more durable and effective responses — aiming to reshape the future of cancer treatment.

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers. .$AKTX #AntibodyDrugConjugates #ADC #Oncology

RT @InvestorVirtual: Abizer Gaslightwala, CEO of @akaritx, shares his bold vision to revolutionize cancer care with Akari’s cutting-edge PH….

Akari Therapeutics Participates in the @investorvirtual “What’s Your Story” Summer Spotlight On-Demand Conference. $AKTX #AntibodyDrugConjugates #ADC #Oncology

Discover what sets Akari Therapeutics apart. We are working to advance antibody drug conjugates with novel immuno-oncology payloads. Lear more here: .$AKTX #AntibodyDrugConjugates #ADC #Oncology

Happy Independence Day!. Wishing everyone a safe and joyful Fourth of July filled with celebration, gratitude and time with loved ones.

RT @InvestorVirtual: Abizer Gaslightwala, CEO of @AkariTx, participated in a #WhatThisMeans segment to discuss their recently issued India….

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent. .$AKTX #Oncology #ADCs #AntibodyDrugConjugates

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India. .$AKTX #Oncology #ADCs #AntibodyDrugConjugates

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India. .$AKTX #Oncology #ADCs #AntibodyDrugConjugates

Our technology features a novel anti-cancer payload designed to disrupt RNA splicing within cancer cells—triggering tumor-specific cell death, activating the immune response and minimizing off-target toxicity. #AKTX is working to overcome the shortcomings of current #ADCs.

#StartingSoon⏰! We will be live at 2:20 PM ET in the Biotech Investment Webinar, hosted by @WebullGlobal Corporate Connect. Join us to explore what’s next for $AKTX:  . #Oncology #ADCs #AntibodyDrugConjugates